by
Ioannis Zabetakis, @yanzabet
The regular followers of this op-ed column would remember that there are two school of thoughts in order to fight the Cardiovascular Diseases (CVDs).
One school of thought believes in the use of statins to reduce plasma cholesterol and the other school of thought, where we belong, puts inflammation rather than cholesterol in the epicentre of our fight against CVDs.
Last May, a very interesting paper titled “The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations” was published [1].
The abstract of this paper reads: “Recent studies have demonstrated a higher risk of incident diabetes associated with statin use, causing concern among patients and clinicians. In this review, we will assess the evidence and proposed mechanisms behind statin therapy and its association with incident diabetes. We will then review the current recommendations for statin use in light of this association and suggest next steps for clinicians managing these patients and researchers exploring this phenomenon”.
The authors have found that “the annual risk of developing new-onset diabetes with statin treatment is approximately 0.1 percent. In comparison, the absolute risk reduction of major coronary events with statin use is approximately 0.42 percent annually. Statins are associated with the development of incident diabetes, particularly among those with predisposing risk factors for diabetes. However, the benefit of statin use among these patients in preventing major coronary events strongly favours statin use despite its risk of incident diabetes”.
Read the full article, HERE.
The regular followers of this op-ed column would remember that there are two school of thoughts in order to fight the Cardiovascular Diseases (CVDs).
One school of thought believes in the use of statins to reduce plasma cholesterol and the other school of thought, where we belong, puts inflammation rather than cholesterol in the epicentre of our fight against CVDs.
Last May, a very interesting paper titled “The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations” was published [1].
The abstract of this paper reads: “Recent studies have demonstrated a higher risk of incident diabetes associated with statin use, causing concern among patients and clinicians. In this review, we will assess the evidence and proposed mechanisms behind statin therapy and its association with incident diabetes. We will then review the current recommendations for statin use in light of this association and suggest next steps for clinicians managing these patients and researchers exploring this phenomenon”.
The authors have found that “the annual risk of developing new-onset diabetes with statin treatment is approximately 0.1 percent. In comparison, the absolute risk reduction of major coronary events with statin use is approximately 0.42 percent annually. Statins are associated with the development of incident diabetes, particularly among those with predisposing risk factors for diabetes. However, the benefit of statin use among these patients in preventing major coronary events strongly favours statin use despite its risk of incident diabetes”.
Read the full article, HERE.
The Aquaculturists
This blog is maintained by The Aquaculturists staff and is supported by the
magazine International Aquafeed which is published by Perendale Publishers Ltd
For additional daily news from aquaculture around the world: aquaculture-news
No comments:
Post a Comment